Top Markets
#1 ADO Protocol ADO Protocol +337.34%
#2 GoPlus Security GoPlus Security +56.76%
#3 The Black Bull The Black Bull +52.61%
#4 Nockchain Nockchain +49.55%
#5 Tutorial Tutorial +49.26%
#6 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +41.29%
#7 Starpower Starpower +35.24%
#8 GAIB AID GAIB AID +24.67%
#9 Fake World Assets Fake World Assets +16.40%
#10 Casper Network Casper Network +15.91%
Coin of the day
ADO Protocol ADO Protocol
Configurações
Idioma
PORTUGUêS
Moeda
USD
Tema
Cuprina Holdings (Cayman) Limited Class A Ordinary Shares Cuprina Holdings (Cayman) Limited Class A Ordinary Shares

Cuprina Holdings (Cayman) Limited Class A Ordinary Shares

CUPR
Classificação em ações #33289
Cuprina Holdings (Cayman) Limited is a Singaporean biotechnology and biomedical... Cuprina Holdings (Cayman) Limited is a Singaporean biotechnology and biomedical enterprise, primarily dedicated to pioneering and bringing to market advanced solutions for the management of persistent wounds. The company produces and supplies its flagship MEDIFLY brand, which features medical-grade sterile blowfly larvae bio-dressing products designed to function as an effective biological debridement tool for chronic wounds. Beyond its core wound care business, Cuprina also extends its operations into the broader health and beauty market, where it provides a range of cosmeceutical items.
Preço da ação
$2.93
Valor de mercado
$7.86M
Variação (1 dia)
-2.66%
Variação (1 ano)
-69.22%
País
SG
Negociar Cuprina Holdings (Cayman) Limited Class A Ordinary Shares (CUPR)

Categoria

Healthcare
Lucros da Cuprina Holdings (Cayman) Limited Class A Ordinary Shares (CUPR)
Lucros em 2026 TTM: 0
De acordo com os últimos relatórios financeiros da Cuprina Holdings (Cayman) Limited Class A Ordinary Shares, os ganhos atuais da empresa são de 0. Em 2026, a empresa teve ganhos de 0, igual a aos ganhos de 2026, que foram de 0. Os ganhos apresentados nesta página são os ganhos antes de juros e impostos, conhecidos como EBIT.
Histórico de lucros da Cuprina Holdings (Cayman) Limited Class A Ordinary Shares de 2026 a 2026
Lucros no final de cada ano
Ano Lucros Alterar
Não há dados suficientes para as datas fornecidas.
Lucros de empresas semelhantes ou concorrentes
Empresa Lucros Diferença de Lucros País
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
$3.01B -
BE